Paragon Bioservices, the private equity-backed biologics contract development and manufacturing organization (CDMO) who was recently acquired by Catalent, has appointed John Mosack as the vice president of manufacturing for its clinical through commercial-scale gene therapy facility in Baltimore, MD. Additionally, Paragon has appointed Adam Sachs as the vice president of program management and strategic client alliance to further support its customers throughout the life cycle of their product.
 
“These two new positions allow Paragon to create a true environment of excellence in manufacturing,” said Pete Buzy, president and chief exeutive officer, Paragon. “John’s extensive experience with high-quality GMP production facilities will be a great asset to the Paragon team. Additionally, Adam’s focus on client deliverables and timelines will provide our customers with the support and attention needed for the future success of their products.”
 
Mr. Mosack joins Paragon with over 25 years of GMP operations management, validation and compliance experience in small- and large-scale clinical and commercial biologics manufacturing operations. Most recently, he was the site head for Lonza’s bioscience and cell therapy operations at the Walkersville, MD production facility.
 
Mr. Sachs joins Paragon with over 25 years of experience in program and alliance management, operations/supply chain management and business development within the biotech and pharma industries. He’s spent the past ten years at AstraZeneca/MedImmune where he served as senior director in both business development and alliance management.
 
In addition to the two new leadership positions, Paragon recently promoted Deborah Wild to chief quality and regulatory affairs officer. She brings to the new position more than 30 years of experience. Most recently, she ran a consulting practice where she led quality assurance-focused initiatives clients such as Genentech, TEVA, Polynoma, Cytovance and CMC Biologics.
 
Paragon recently announced plans to expand its operations on the BWI campus with a second GMP gene therapy production facility. The campus currently holds 200,000 square-feet of state-of-the-art GMP gene therapy biomanufacturing space that is equipped with 500L and 2000L single-use bioreactors for clinical trial and commercial material production.